Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis
In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.
By
Kerri Miller
March 17, 2026
Clinical Scorecard: Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis
At a Glance
Category Detail
Condition Moderate-to-severe Atopic Dermatitis in pediatric patients Key Mechanisms Monoclonal antibody targeting interleukin-13 to inhibit inflammation and barrier dysfunction Target Population Pediatric patients aged 6 months to 18 years Care Setting Phase 3 clinical trial (ADorable-1)
Key Highlights
63% of patients on lebrikizumab achieved at least a 75% reduction in EASI score 44% achieved an IGA score of 0 or 1, indicating clear or almost clear skin 39% achieved a 90% reduction in EASI score at Week 16 Safety profile consistent with prior studies, no new safety signals reported Ongoing long-term extension study (ADorable-2) planned for up to 52 weeks Guideline-Based Recommendations
Diagnosis
Assess severity of atopic dermatitis using EASI and IGA scores Management
Consider lebrikizumab for moderate-to-severe atopic dermatitis in pediatric patients Monitoring & Follow-up
Monitor for efficacy and adverse events during treatment Risks
Common adverse events include upper respiratory tract infections and nasopharyngitis Patient & Prescribing Data
Pediatric patients with moderate-to-severe atopic dermatitis
Lebrikizumab shows significant efficacy in reducing skin inflammation and itch
Clinical Best Practices
Initiate topical corticosteroids prior to randomization and continue during treatment Evaluate treatment response at Week 16 using EASI and IGA scores References
